{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DART", "query": { "intervention": "DART" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 49, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DART&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T01:12:42.584Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02628535", "title": "Safety Study of MGD009 in B7-H3-expressing Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mesothelioma", "Bladder Cancer", "Melanoma", "Squamous Cell Carcinoma of the Head and Neck", "Non Small Cell Lung Cancer", "Clear Cell Renal Cell Carcinoma", "Ovarian Cancer", "Thyroid Cancer", "Breast Cancer", "Pancreatic Cancer", "Prostate Cancer", "Colon Cancer", "Soft Tissue Sarcoma" ], "interventions": [ { "name": "MGD009", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2015-09", "completion_date": "2019-11-25", "has_results": false, "last_update_posted_date": "2022-02-08", "last_synced_at": "2026-09-03T01:12:42.584Z", "location_count": 14, "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02628535" }, { "nct_id": "NCT02834013", "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acinar Cell Carcinoma", "Adenoid Cystic Carcinoma", "Adrenal Cortical Carcinoma", "Adrenal Gland Pheochromocytoma", "Anal Canal Neuroendocrine Carcinoma", "Anal Canal Undifferentiated Carcinoma", "Angiosarcoma", "Apocrine Neoplasm", "Appendix Mucinous Adenocarcinoma", "Bartholin Gland Transitional Cell Carcinoma", "Basal Cell Carcinoma", "Bladder Adenocarcinoma", "Breast Metaplastic Carcinoma", "Cervical Adenocarcinoma", "Cholangiocarcinoma", "Chordoma", "Colorectal Squamous Cell Carcinoma", "Desmoid Fibromatosis", "Endometrial Transitional Cell Carcinoma", "Endometrioid Adenocarcinoma", "Esophageal Neuroendocrine Carcinoma", "Esophageal Undifferentiated Carcinoma", "Extrahepatic Bile Duct Carcinoma", "Extramammary Paget Disease", "Fallopian Tube Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fibromyxoid Tumor", "Gallbladder Carcinoma", "Gastric Neuroendocrine Carcinoma", "Gastric Squamous Cell Carcinoma", "Gastric Undifferentiated Carcinoma", "Gastrointestinal Stromal Tumor", "Gestational Trophoblastic Tumor", "Giant Cell Carcinoma", "Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type", "Intestinal Neuroendocrine Carcinoma", "Intrahepatic Cholangiocarcinoma", "Lung Neuroendocrine Tumor", "Lung Sarcomatoid Carcinoma", "Major Salivary Gland Carcinoma", "Malignant Neoplasm of Unknown Primary", "Malignant Odontogenic Neoplasm", "Malignant Peripheral Nerve Sheath Tumor", "Malignant Solid Neoplasm", "Malignant Testicular Sex Cord-Stromal Tumor", "Metastatic Pituitary Neuroendocrine Tumor", "Minimally Invasive Lung Adenocarcinoma", "Mixed Mesodermal (Mullerian) Tumor", "Mucinous Adenocarcinoma", "Mucinous Cystadenocarcinoma", "Nasal Cavity Adenocarcinoma", "Nasal Cavity Carcinoma", "Nasopharyngeal Carcinoma", "Nasopharyngeal Low Grade Papillary Adenocarcinoma", "Nasopharyngeal Undifferentiated Carcinoma", "Oral Cavity Carcinoma", "Oropharyngeal Undifferentiated Carcinoma", "Ovarian Adenocarcinoma", "Ovarian Germ Cell Tumor", "Ovarian Mucinous Adenocarcinoma", "Ovarian Squamous Cell Carcinoma", "Ovarian Transitional Cell Carcinoma", "Pancreatic Acinar Cell Carcinoma", "Pancreatic Neuroendocrine Carcinoma", "Paraganglioma", "Paranasal Sinus Adenocarcinoma", "Paranasal Sinus Carcinoma", "Parathyroid Gland Carcinoma", "PEComa", "Penile Squamous Cell Carcinoma", "Peritoneal Mesothelial Neoplasm", "Placental Choriocarcinoma", "Primary Peritoneal High Grade Serous Adenocarcinoma", "Pseudomyxoma Peritonei", "Rare Disorder", "Scrotal Squamous Cell Carcinoma", "Seminal Vesicle Adenocarcinoma", "Seminoma", "Serous Cystadenocarcinoma", "Small Intestinal Adenocarcinoma", "Small Intestinal Squamous Cell Carcinoma", "Spindle Cell Neoplasm", "Teratoma With Somatic-Type Malignancy", "Testicular Non-Seminomatous Germ Cell Tumor", "Thyroid Gland Carcinoma", "Tracheal Carcinoma", "Transitional Cell Carcinoma", "Ureter Adenocarcinoma", "Ureter Squamous Cell Carcinoma", "Urethral Adenocarcinoma", "Urethral Squamous Cell Carcinoma", "Vaginal Adenocarcinoma", "Vaginal Squamous Cell Carcinoma, Not Otherwise Specified", "Vulvar Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 798, "start_date": "2017-01-30", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-09-03T01:12:42.584Z", "location_count": 1006, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 620 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02834013" }, { "nct_id": "NCT05506956", "title": "Post-transplant Flotetuzumab for AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Myeloid, Acute" ], "interventions": [ { "name": "Flotetuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2022-10-20", "completion_date": "2024-06-18", "has_results": true, "last_update_posted_date": "2025-09-12", "last_synced_at": "2026-09-03T01:12:42.584Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05506956" }, { "nct_id": "NCT07308717", "title": "Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) Protocol", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Modification to Pre-operative Order Set", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1896, "start_date": "2025-12-16", "completion_date": "2027-12-16", "has_results": false, "last_update_posted_date": "2025-12-30", "last_synced_at": "2026-09-03T01:12:42.584Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07308717" }, { "nct_id": "NCT00116116", "title": "DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections", "AIDS" ], "interventions": [ { "name": "efavirenz, stavudine extended release, lamivudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2002-03", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2011-04-26", "last_synced_at": "2026-09-03T01:12:42.584Z", "location_count": 10, "location_summary": "Bakersfield, California • San Francisco, California • Washington D.C., District of Columbia + 7 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00116116" }, { "nct_id": "NCT06218199", "title": "Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Heart Failure, Congestive" ], "interventions": [ { "name": "Furosemide", "type": "DRUG" }, { "name": "Torsemide", "type": "DRUG" }, { "name": "Bumetanide", "type": "DRUG" }, { "name": "sacubitril/valsartan", "type": "DRUG" }, { "name": "Hydralazine", "type": "DRUG" }, { "name": "Isosorbide Dinitrate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Heart Center Research, LLC", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 80, "start_date": "2021-07-08", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2024-01-29", "last_synced_at": "2026-09-03T01:12:42.584Z", "location_count": 1, "location_summary": "Huntsville, Alabama", "locations": [ { "city": "Huntsville", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT06218199" }, { "nct_id": "NCT04482621", "title": "Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "Placebo Saline", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2020-09-14", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-08-29", "last_synced_at": "2026-09-03T01:12:42.584Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04482621" }, { "nct_id": "NCT01523964", "title": "DART Electrical Impedance Myography (EIM) Trial in Duchenne Muscular Dystrophy (DMD) and Healthy Controls", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Duchenne Muscular Dystrophy" ], "interventions": [ { "name": "Testing with EIM", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Dart Therapeutics. LLC", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "3 Years", "maximum_age": "12 Years", "sex": "MALE", "summary": "3 Years to 12 Years · Male only" }, "enrollment_count": 92, "start_date": "2012-02", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2013-12-09", "last_synced_at": "2026-09-03T01:12:42.584Z", "location_count": 6, "location_summary": "Aurora, Colorado • Boston, Massachusetts • St Louis, Missouri + 3 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01523964" }, { "nct_id": "NCT03522740", "title": "Decision Aid for Renal Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Kidney Diseases", "Kidney Failure, Chronic" ], "interventions": [ { "name": "Decision Aid for Renal Therapy", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Tufts University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": null, "sex": "ALL", "summary": "70 Years and older" }, "enrollment_count": 400, "start_date": "2018-05-30", "completion_date": "2021-09-21", "has_results": false, "last_update_posted_date": "2022-04-27", "last_synced_at": "2026-09-03T01:12:42.584Z", "location_count": 4, "location_summary": "San Diego, California • Chicago, Illinois • Portland, Maine + 1 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Portland", "state": "Maine" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03522740" }, { "nct_id": "NCT02152956", "title": "Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "AML" ], "interventions": [ { "name": "Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose", "type": "BIOLOGICAL" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 244, "start_date": "2014-06-09", "completion_date": "2022-07-05", "has_results": true, "last_update_posted_date": "2024-01-30", "last_synced_at": "2026-09-03T01:12:42.584Z", "location_count": 20, "location_summary": "Duarte, California • La Jolla, California • San Francisco, California + 16 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02152956" } ] }